Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Caribou Biosciences (CRBU) Equity Average (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Equity Average for 6 consecutive years, with $132.0 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 50.57% to $132.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $132.0 million through Dec 2025, down 50.57% year-over-year, with the annual reading at $187.6 million for FY2025, 39.63% down from the prior year.
  • Equity Average for Q4 2025 was $132.0 million at Caribou Biosciences, down from $154.0 million in the prior quarter.
  • The five-year high for Equity Average was $396.1 million in Q4 2021, with the low at -$41.7 million in Q2 2021.
  • Average Equity Average over 5 years is $256.5 million, with a median of $292.7 million recorded in 2023.
  • Peak annual rise in Equity Average hit 2497.89% in 2021, while the deepest fall reached 1346.31% in 2021.
  • Over 5 years, Equity Average stood at $396.1 million in 2021, then dropped by 21.11% to $312.5 million in 2022, then increased by 22.67% to $383.3 million in 2023, then plummeted by 30.33% to $267.1 million in 2024, then crashed by 50.57% to $132.0 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $132.0 million, $154.0 million, and $191.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.